Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL571673 | 1.00 | SERPINE1 (0.46) | SERPINE1MAPTGAAGLAHCAR3 | |
| SCHEMBL572283 | 0.91 | MAPT (0.43) | SERPINE1MAPTGAAGLAHCAR3 | |
| SCHEMBL572284 | 0.91 | MAPT (0.43) | SERPINE1MAPTGAAGLAHCAR3 | |
| SCHEMBL571675 | 0.84 | ALDH1A1 (0.37) | SERPINE1GAAALDH1A1 | |
| SCHEMBL25407181 | 0.81 | MAPT (0.40) | SERPINE1MAPTGAAGLAHCAR3 | |
| SCHEMBL25407187 | 0.81 | MAPT (0.40) | SERPINE1MAPTGAAGLAHCAR3 | |
| SCHEMBL15192827 | 0.77 | CYP2C19 (0.45) | MAPTGAAGLAALDH1A1CYP1A2 | |
| SCHEMBL572759 | 0.75 | PDGFRB (0.37) | MAPTGAAALDH1A1HTT | |
| SCHEMBL572758 | 0.75 | PDGFRB (0.37) | MAPTGAAALDH1A1HTT | |
| SCHEMBL15199158 | 0.74 | MAPT (0.46) | SERPINE1MAPTGAAGLAHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160046625-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC (US) | 2016-02-18 | — | — | US | disclosed |
| US-9115127-B2 | Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase | AMGEN INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20130217668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2013-08-22 | — | — | US | disclosed |
| EP-2611784-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | Amgen, Inc (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012018668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046625-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | BCL6, DCK, FLI1 | SERPINE1 2456/4885MAPT 3852/4885GAA 1471/4885 |
| US-20130217668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | BCL6, DCK, FLI1 | SERPINE1 2456/4885MAPT 3852/4885GAA 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.